JPRN-jRCTs041220114招募中2 期
The single-center phase II study for the efficacy of proton pump inhibitor for postoperative delirium in elderly patients undergoing hepatobiliary and pancreatic surgery
Sugiura Teiichi0 个研究点目标入组 82 人开始时间: 2022年12月27日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 82
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 70age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patients scheduled for elective hepatectomy or pancreatectomy for liver, biliary, pancreatic, and duodenal diseases
- •2.Age >= 70 years
- •3.Eastern Cooperative Oncology Group performance status of 0 or 1
- •4.Ability to undergo the Confusion Assessment Method-Intensive Care Unit (CAM-ICU)
- •5.Written informed consent
排除标准
- •1.Patients scheduled for laparoscopic surgery.
- •2.Patients scheduled for hepatectomy combined with pancreatectomy.
- •3.Patients with dementia
- •4.Patients with a history of delirium
- •5.Patients diagnosed with psychological disorders such as alcoholism
- •6.Patients with habitual use of benzodiazepine receptor agonitst
- •7.Patients with habitual use of histamine H2-receptor antagonists within a week before registration
- •8.Patients with a history of hypersensitivity to proton pump inhibitor
- •9.Patients with habitual use of opioids or steroids
- •10.Patients who are determined not applicable for the study by the physician
研究者
相似试验
尚未招募
2 期
Phase II single centre study assessing the efficacy and safety of I-131 rituximab radioimmunotherapy of relapsed or refractory diffuse large B cell lymphoma.Diffuse large B cell lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaACTRN12605000236695Fremantle Hospital & Health Service40
进行中（未招募）
1 期
Behandlung von Patienten mit einer Akuten Myeloischen Leukämie mit einer c-KIT oder FLT3-ITD Mutation in Verbindung mit einer t(8;21) Mutation mit Midostaurin zusätzlich zur Standard-ChemotherapiePatients with newly diagnosed c-KIT or FLT3-ITD mutated t(821) AMLMedDRA version: 21.1 Level: LLT Classification code 10060557 Term: Acute myelocytic leukemia System Organ Class: 100000004864EUCTR2011-002567-17-DETechnische Universität Dresden18
进行中（未招募）
1 期
A phase II study of linperlisib (YY-20394) in patients with relapsed or refractory peripheral T/NK cell or Cutaneous T Cell lymphomaCTIS2022-501431-16-00Shanghai Yingli Pharmaceutical Co. Ltd.107
进行中（未招募）
不适用
A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with metastatic renal cell cancer (Bevacizumab with standard therapy in RCC) - Bevacizumab with standard therapy in RCCMetastatic renal cell cancerEUCTR2005-006161-13-DERoche Pharma AG
招募中
2 期
A study to check the efficacy of Osimertinib when given with Savolitinib in Patients with Lung Cancer who have progressed after Treatment with OsimertinibCTRI/2019/08/020845AstraZeneca AB